地高辛联合环磷腺苷葡胺治疗慢性肺源性心脏病心力衰竭的临床疗效

Clinical Efficacy of Digoxin Combined with Cyclophosphine Adenosine Glucosamine in the Treatment of Heart Failure in Patients with Chronic Pulmonary Heart Disease

目的研究慢性肺源性心脏病心力衰竭临床接受地高辛联合环磷腺苷葡胺治疗的效果。方法以该院2017年9月—2019年8月共86例慢性肺源性心脏病心力衰竭患者为对象,均接受常规治疗,将患者分为两组,52例接受地高辛联合环磷腺苷葡胺治疗,视作观察组,34例单用地高辛、环磷腺苷葡胺治疗,或不应用上述两种及其他改善心功能药物治疗,视作对照组,比较两组症状改善情况、住院时间。结果观察组治疗后症状积分为(4.15±0.81)分,低于对照组(8.71±1.42)分(t=18.949,P<0.05);观察组住院时间为(12.53±3.62)d,对照组(17.84±4.15)d(t=6.275,P<0.05),观察组出院后再次入院率为3.85%,明显低于对照组23.53%(χ^2=7.751,P<0.05);观察组接受联合治疗后BNP水平为(532.16±80.27)pg/mL,明显低于对照组治疗后BNP水平为(678.41±95.64)pg/mL(t=15.274,P<0.05)。结论地高辛联合环磷腺苷葡胺治疗慢性肺源性心脏病心力衰竭能够更明显缓解患者临床症状,缩短患者住院时间,降低出院后再入院率,疗效明显更优,值得推广。

Objective To study the effect of digoxin combined with meglumine cyclophosphate in the treatment of chronic pulmonary heart failure.Methods A total of 86 patients with chronic pulmonary heart disease and heart failure in the hospital from September 2017 to August 2019 were divided into two groups.52 patients were treated with digoxin combined with meglumine cyclophosphate as observation group,34 patients were treated with digoxin alone,meglumine cyclophosphate,or not treated with the above two kinds of drugs and other drugs to improve cardiac function,and the control group was treated with digoxin combined with meglumine cyclophosphate.The improvement of symptoms and hospital stay were compared between the two groups.Results The observation group was treated with treatment.The score of symptoms was(4.15±0.81)points,which was lower than that of the control group(8.71±1.42)points(t=18.949,P<0.05),the hospitalization time of the observation group was(12.53±3.62)d,the control group(17.84±4.15)d(t=6.275,P<0.05),and the re-admission rate of the observation group was 3.85%,which was significantly lower than that of the control group 23.53%.The level of BNP in the observation group was(532.16±80.27)pg/mL,after combined treatment,which was significantly lower than that in the control group.The level of BNP in group B was(678.41±95.64)pg/mL after treatment(P<0.05).Conclusion Digoxin combined with meglumine cyclophosphate can relieve the clinical symptoms of patients with chronic pulmonary heart failure,shorten the hospitalization time,reduce the rate of readmission after discharge,and the curative effect is obviously better,which is worth popularizing.